Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Holding INCY?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.49Last Year’s EPS
$1.06Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2024
|% Change Since: 4.80%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong performance by Incyte, with significant revenue growth and key product approvals. The pipeline is progressing well with several promising developments. However, there were notable increases in R&D and SG&A expenses. Overall, the positive aspects outweigh the negatives, indicating a strong quarter for Incyte.Company Guidance
During the Q3 2024 earnings call, Incyte provided guidance that highlighted significant commercial performance and clinical advancements. The company reported a 24% year-over-year increase in total revenues, reaching $1.1 billion, with net product revenues growing by 23%. Jakafi generated $731 million in net product revenue, reflecting a 16% year-over-year increase driven by a 10% rise in paid demand. Opzelura also showed strong performance with $139 million in net product revenues, up 52% from the same quarter last year. Consequently, Incyte raised its full-year 2024 Jakafi net revenue guidance to a range of $2.74 billion to $2.77 billion. Additionally, the FDA approved Niktimvo for chronic graft-versus-host disease, and the company anticipates launching it in the U.S. in the first quarter of 2025.Revenue Growth
Total revenues increased by 24% year-over-year to $1.1 billion, with net product revenues growing 23%.
FDA Approval of Niktimvo
Niktimvo was approved for chronic graft-versus-host disease, becoming the first anti-CSF-1R approved for this indication.
Jakafi Performance
Jakafi net product revenue reached $731 million, up 16% year-over-year, with paid demand increasing 10%.
Opzelura Revenue Increase
Opzelura net product revenues were $139 million, up 52% from the same quarter last year.
Pipeline Progress
Positive advancements in the pipeline, including a supplemental NDA filing for ruxolitinib cream and promising data for povorcitinib.
Strong Financial Performance
Total revenues of $1.14 billion, up 24% year-over-year, driven by strong demand for Jakafi and Opzelura.
Increase in Full Year Guidance
Raised full year 2024 Jakafi net revenue guidance to a range of $2.74 billion to $2.77 billion.
---
INCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 29, 2024 | $65.69 | $73.60 | +12.04% |
| Jul 30, 2024 | $68.59 | $67.79 | -1.17% |
| Apr 30, 2024 | $52.56 | $52.05 | -0.97% |
| Feb 13, 2024 | $57.84 | $59.34 | +2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Incyte Corp (INCY) report earnings?
Incyte Corp (INCY) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Incyte Corp (INCY) earnings time?
Incyte Corp (INCY) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INCY EPS forecast?
INCY EPS forecast for the fiscal quarter 2024 (Q4) is $1.49.
---